Battle Lines Drawn In New Renal Anemia Market
Executive Summary
The treatment landscape in renal anemia is set for major changes over the next few years as a novel class of drugs approaches the market. A new report from Biomedtracker looks at the major players battling it out in the clinic.
You may also be interested in...
Phase III Roxadustat ALPS Data Positive For New Class Of Anemia Therapies
Positive top-line data from the ALPS study confirms the efficacy and safety of roxadustat, a Phase III-stage product which could be the first a new class of orally active agents with potential in the treatment of anemia associated with chronic kidney disease.
Finance Watch: Hua Medicine Raises $117.4m While Evaluating A Hong Kong IPO
Hua, already considering an IPO in Hong Kong for up to $400m, closed concurrent VC rounds that will fund its late-stage diabetes program in China, but it may still need to go public to enter other markets. Also, Heron raised cash for its next commercial product, among other public company financings.
AstraZeneca's Pipeline Reaps Rewards Of Return To Science
AstraZeneca rounded off a busy 2017 full of R&D highs, but some huge lows, with a full Phase III pipeline that it says shows how far the company has come since Pascal Soriot took the reins in 2012 and spearheaded a renewed focus on science. But will the company become a victim of its own success?